CMA stated that “there is some benefit, particularly for business certainty, in there being consistency as between the UK and the EU.”46 This applies more widely than just in the area of competition and consumer protection, although the overall impact of divergence on trade with the EU is not yet clear. FSA suggested that a UK producer of cannabidiol (CBD) products may not be able to sell them in the EU when the EU has completed its own risk assessments. FSA also acknowledged a potential risk around how the EU might treat “contamination”, for example for crops grown near to those which have been gene-edited, but did not appear to have deeply considered the issue.47 As FSA spelt out in the case of titanium dioxide, Northern Ireland remains subject to EU rules and this will affect its access to products if these rules differ to those in the UK.48